Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP.

Slides:



Advertisements
Similar presentations
Host Defenses, Microbial Evasion & Virulence Factors
Advertisements

SC Standard Compare the body shapes of bacteria * Spiral * Coccus * Bacillus.
Laboratory of Immunobiochemistry Site Visit
Host-Pathogen Interactions. Symbiosis Commensual Mutualistic Parasitic.
Overview of Laboratory of Bacterial Polysaccharides By Willie F. Vann, Chief LBP.
Laboratory of Respiratory and Special Pathogens. History of the Laboratories Laboratory of Pertussis Laboratory of Respiratory and Special Pathogens Laboratory.
 Mucous membranes –Conjunctiva –Respiratory –Gastrointestinal tract –Urogenital  Skin –Abrasions or bite  Parenteral –Puncture or injection Portals.
Mechanisms of Pathogenicity Microbiology 2314 Definitions Pathogenicity The ability of a pathogen to produce a disease by overcoming the defenses of.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 25 October 2013.
Office of Biotechnology Products
Overview of the Division of Viral Products
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Overview of Laboratory of Bacterial Polysaccharides Willie F. Vann, Ph.D. Chief, Laboratory of Bacterial Polysaccharides.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Michael J. Brennan, Ph.D. for Kathryn M. Carbone, M.D. Associate Director for.
Bacterial Toxins Chapter 14 Add-on.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 28 February 2012.
GRAM POSITIVE & GRAM NEGATIVE BACTERIA
BIO 411 – Medical Microbiology Chapter 9 Commensal and Pathogenic Microbial Flora.
Infection and Disease II Pathogenicity and Infection.
Sequencing capacitiesacademic company based microarray facilitiesacademic company based bioinformaticsacademic proteomic facilitiesacedemic Genome Research.
Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
Establishment of Infection In order to cause disease pathogen must follow a series of steps –Gain entrance to host –Adherence –Colonization –Avoid Host.
Immunoprevention. Definition By using immunological agents to construct, improve or inhibit immune response, people can prevent some diseases.
1 GRAM POSITIVE & GRAM NEGATIVE BACTERIA Dr. Fawzia Al-O tabi.
Commercial Production of Antibiotics
Local Emergency Response to Biohazardous Incidents Dr. Elizabeth Whalen, MD Medical Director Albany County Health Department April 8, 2005 Northeast Biological.
Laboratory of Enteric and Sexually Transmitted Diseases Historical Perspective Origin: Began in Established to review the rapidly increasing.
بسم الله الرحمن الرحيم GENUS: BORDETELLA Prof. Khalifa Sifaw Ghenghesh.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Medical biology, microbiology, virology, immunology department by As.Prof. O.V. Pokryshko Microbial Mechanisms of Pathogenicity.
Small Talk Cell-to-Cell Communication in Bacteria.
Laboratory of Mycobacterial Diseases and Cellular Immunology Center for Biologics Evaluation and Research.
Chapter 15 Microbial Mechanism of Pathogenicity. Pathogens have to enter the system to cause disease Regions/areas of the body used by microbes to enter.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP.
A study of Epidemiology
LIB site visit January 24, 2002 Jay E. Slater, MD Laboratory of Immunobiochemistry FDA/CBER/OVRR/DBPAP.
Pathogenesis of bacterial Infections
Chapter 26 Infectious Diseases.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
Batterjee Medical College. Dr. Manal El Said Department Head of Microbiology Antimicrobial Drugs: Mechanism of Action.
Biologics. Biologics Wide range of medicinal products produced by biological processes. Isolated from a variety of natural sources and may be produced.
The V. fischeri Autoinducer N-(b-ketocaproyl)-L-homoserine lactone.
GRAM POSITIVE & GRAM NEGATIVE BACTERIA
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1 GRAM POSITIVE & GRAM NEGATIVE BACTERIA Dr. Fawzia AL-Otaibi.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 12 May 2011.
Laboratory of Methods Development and Quality Control Laboratory Overview September 22, 2005.
Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 18 March 2009.
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
Office of Vaccines Research and Review
Antimicrobial vaccines List the main types of immunization List the main types of vaccines Describe the advantages and disadvantages of different types.
Overview Laboratory of Bacterial Polysaccharides From cover - Science, 23 March, 2001.
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
Part II: Reproduction and pathogenic bacteria. Review: Structure of bacteria:
Bergey's Phylogenetic In 1923 David Bergey published Bergey's Manual of Determinative It arranged bacteria in 10 orders.
CLASSIFICATION OF MEDICALLY IMPORTANT BACTERIA I. Rigid, thick–walled cell II. Flexible, thin-walled cells, III. Wall-less cells,
Prof. Ramesh Wigneshweraraj
Helpful and Harmful Bacteria
INTRODUCTION TO MEDICAL MICROBIOLOGY & IMMUNOLOGY
Pathogenicity and virulence
Host Parasite Relationship
Bacteria Research.
Presentation transcript:

Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP

2/15 Division of Bacterial, Parasitic and Allergenic Products (DBPAP) Merger (1999) of Division of Bacterial Products (DBP) and Division of Allergenic Products and Parasitology (DAPP) Leadership Drusilla Burns, PhD (Acting) Richard Walker, PhD Milan Blake, PhD Jay Slater, MD 2010-present

3/15 Division of Bacterial, Parasitic and Allergenic Products (DBPAP) Immediate Office of the Director Jay Slater, MD – Director Drusilla Burns, PhD – Deputy Director (Acting) Regulatory Staff Jennifer Bridgewater – Assoc. Dir. Regulatory Policy Tina Roecklein – Regulatory Coordinator 5 FTE Laboratory of Respiratory and Special Pathogens Drusilla Burns, PhD - Chief Juan Arciniega, D Sci James Keller, PhD Tod Merkel, PhD Michael Schmitt, PhD 16 FTE, 7 ORISE Laboratory of Bacterial Polysaccharides Willie Vann, PhD – Chief Mustafa Akkoyunlu, PhD Margaret Bash, MD Wei Wang, PhD John Cipollo, PhD Daron Freedberg, PhD 16 FTE, 11 ORISE Laboratory of Enteric and Sexually Transmitted Diseases Scott Stibitz, Ph.D. – Chief Dennis Kopecko, PhD 7 FTE, 13 ORISE Laboratory of Mycobacterial Diseases & Cellular Immunology Sheldon Morris, Ph.D. – Chief Siobhan Cowley, PhD Karen Elkins, PhD 10 FTE, 9 ORISE As of 15 April 2011 Laboratory of Immunobiochemisty Ron Rabin, M.D. – Chief 9 FTE, 7 ORISE

4/15 DBPAP regulatory/research portfolio Non-invasive, toxin producers Bacillus anthracis (Bordetella parapertussis) Bordetella pertussis (Clostridium botulinum) Clostridium tetani Corynebacterium diphtheriae Invasive, protective responses to polysaccharides Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Intracellular (Francisella tularensis) Mycobacterium tuberculosis Mycobacterium bovis Enteric (Campylobacter jejuni) Salmonella typhi (Salmonella typhimurium) (Shigella dysenteriae) Parasite (Plasmodium spp) Other/emerging (Yersinia pestis) (Staphylococcus aureus) Allergenic products (Probiotics)

5/15 DBPAP regulatory/research portfolio Bacterial Polysaccharides (LBP) Non-invasive, toxin producers Bacillus anthracis (Bordetella parapertussis) Bordetella pertussis (Clostridium botulinum) Clostridium tetani Corynebacterium diphtheriae Invasive, protective responses to polysaccharides Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Intracellular (Francisella tularensis) Mycobacterium tuberculosis Mycobacterium bovis Enteric (Campylobacter jejuni) Salmonella typhi (Salmonella typhimurium) (Shigella dysenteriae) Parasite (Plasmodium spp) Other/emerging (Yersinia pestis) (Staphylococcus aureus) Allergenic products (Probiotics)

6/15 Bacterial polysaccharides (LBP) Akkoyunlu Regulation of humoral immune response against polysaccharide vaccines by bacterial products Bash To present protein targets as alternatives based on molecular epidemiology of the pathogen where polysaccharide vaccines have lacked success Cipollo Mass spectrometry of carbohydrates as a tool for characterization of bacterial vaccines and pathogens Freedberg Improvement of biological product quality by application of new technologies to characterize of vaccines and blood products: NMR spectroscopy and light scattering Vann To detemine the metabolic pathway for the synthesis of polysaccharides in gram negative pathogens and to use this knowledge to development methods for preparing glycoconjugate vaccines using metabolic engineering To improve and understand the manufacture of current conjugate vaccines through the investigation of conjugation chemistry Wang To investigate the genetics of pathogenesis of gram negative bacteria. M. catarrhalis is a model organism for these studies. To study the regulation of M. catarrhalis virulence gene expression and identify biomarkers for developing vaccine against M. catarrhalis.

7/15 DBPAP regulatory/research portfolio Enteric and Sexually Transmitted Diseases (LESTD) Non-invasive, toxin producers Bacillus anthracis (Bordetella parapertussis) Bordetella pertussis (Clostridium botulinum) Clostridium tetani Corynebacterium diphtheriae Invasive, protective responses to polysaccharides Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Intracellular (Francisella tularensis) Mycobacterium tuberculosis Mycobacterium bovis Enteric (Campylobacter jejuni) Salmonella typhi (Salmonella typhimurium) (Shigella dysenteriae) Parasite (Plasmodium spp) Other/emerging (Yersinia pestis) (Staphylococcus aureus) Allergenic products (Probiotics)

8/15 Enteric and Sexually Transmitted Diseases (LESTD) Stibitz Molecular genetics of virulence and virulence-gene regulation in bacterial respiratory pathogens Kopecko Evaluate safety and utility of Salmonella typhi Ty21a as an oral vaccine delivery platform for expression of foreign antigens and delivery of anti-cancer therapies Analyze pathogenesis of and immune responses to Campylobacter jejuni infection in humans Evaluate the vaccine potential of inactivated enteric bacteria

9/15 DBPAP regulatory/research portfolio Immunobiochemistry (LIB) Non-invasive, toxin producers Bacillus anthracis (Bordetella parapertussis) Bordetella pertussis (Clostridium botulinum) Clostridium tetani Corynebacterium diphtheriae Invasive, protective responses to polysaccharides Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Intracellular (Francisella tularensis) Mycobacterium tuberculosis Mycobacterium bovis Enteric (Campylobacter jejuni) Salmonella typhi (Salmonella typhimurium) (Shigella dysenteriae) Parasite (Plasmodium spp) Other/emerging (Yersinia pestis) (Staphylococcus aureus) Allergenic products (Probiotics)

10/15 DBPAP regulatory/research portfolio Mycobacterial Diseases and Cellular Immunology (LMDCI) Non-invasive, toxin producers Bacillus anthracis (Bordetella parapertussis) Bordetella pertussis (Clostridium botulinum) Clostridium tetani Corynebacterium diphtheriae Invasive, protective responses to polysaccharides Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Intracellular (Francisella tularensis) Mycobacterium tuberculosis Mycobacterium bovis Enteric (Campylobacter jejuni) Salmonella typhi (Salmonella typhimurium) (Shigella dysenteriae) Parasite (Plasmodium spp) Other/emerging (Yersinia pestis) (Staphylococcus aureus) Allergenic products (Probiotics)

11/15 Mycobacterial Diseases and Cellular Immunology (LMDCI) Elkins Understand innate immune responses to intracellular bacteria in general and LVS in particular, particularly facets with implications for safety and efficacy outcomes. Define mechanisms by which vaccine-induced immune T cells provide protection against intracellular bacteria, and thus establish practical immune correlates Morris Characterization of novel vaccines and immunization strategies against TB Development of assays to facilitate the assessment of TB vaccines Cowley Characterization of unique aspects of mucosal immune responses to intracellular pathogens. Malaria program – collaboration with OBRR

12/15 DBPAP regulatory/research portfolio Respiratory and Special Pathogens (LRSP) Non-invasive, toxin producers Bacillus anthracis (Bordetella parapertussis) Bordetella pertussis (Clostridium botulinum) Clostridium tetani Corynebacterium diphtheriae Invasive, protective responses to polysaccharides Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Intracellular (Francisella tularensis) Mycobacterium tuberculosis Mycobacterium bovis Enteric (Campylobacter jejuni) Salmonella typhi (Salmonella typhimurium) (Shigella dysenteriae) Parasite (Plasmodium spp) Other/emerging (Yersinia pestis) (Staphylococcus aureus) Allergenic products (Probiotics)

13/15 Respiratory and Special Pathogens (LRSP) Arciniega Development and refinement of potency and toxicity tests for bacterial vaccines Burns Bacterial toxin structure/function relationships Study of host response to immunization with anthrax and Staphylococcal aureus vaccines Keller Clostridial neurotoxin vaccine and antitoxin research Merkel Development of animal aerosol challenge models for pertussis, anthrax and disease caused by Staphylococcus aureus. Analysis of gene regulation in Bordetella pertussis Schmitt Characterization of iron transport systems of Corynebacterium diphtheriae Analysis of gene regulation in C. diphtheriae

14/15 Division of Bacterial, Parasitic and Allergenic Products (DBPAP Immediate Office of the Director Jay Slater, MD – Director Drusilla Burns, PhD – Deputy Director (Acting) Regulatory Staff Jennifer Bridgewater – Assoc. Dir. Regulatory Policy Tina Roecklein – Regulatory Coordinator 5 FTE Laboratory of Respiratory and Special Pathogens Drusilla Burns, PhD - Chief Juan Arciniega, D Sci James Keller, PhD Tod Merkel, PhD Michael Schmitt, PhD 16 FTE, 7 ORISE Laboratory of Bacterial Polysaccharides Willie Vann, PhD – Chief Mustafa Akkoyunlu, PhD Margaret Bash, MD Wei Wang, PhD John Cipollo, PhD Daron Freedberg, PhD 16 FTE, 11 ORISE Laboratory of Enteric and Sexually Transmitted Diseases Scott Stibitz, Ph.D. – Chief Dennis Kopecko, PhD 7 FTE, 13 ORISE Laboratory of Mycobacterial Diseases & Cellular Immunology Sheldon Morris, Ph.D. – Chief Siobhan Cowley, PhD Karen Elkins, PhD 10 FTE, 9 ORISE As of 15 April 2011 Laboratory of Immunobiochemisty Ron Rabin, M.D. – Chief 9 FTE, 7 ORISE

15/15 LIB presenters Ronald Rabin, MD (2002) Ashraf El Fiky, MD PhD (2009) Jay E. Slater, MD (1998) Taruna Khurana, PhD (2009)